{"id":"estradiol-dipropionate","rwe":[{"pmid":"41137228","year":"2025","title":"Synergistic target network construction and dynamic simulation analysis based on a prospective systems pharmacology strategy.","finding":"","journal":"Medicine","studyType":"Clinical Study"},{"pmid":"40719002","year":"2025","title":"Multiple Estradiol Benzoate Treatment Enhances Milk Production on Induction of Artificial Lactation in Pseudopregnant Pigs.","finding":"","journal":"Reproduction in domestic animals = Zuchthygiene","studyType":"Clinical Study"},{"pmid":"39840814","year":"2025","title":"Structure and hormonal output of the adrenal gland after experimental estrogenization of male rats.","finding":"","journal":"Histology and histopathology","studyType":"Clinical Study"},{"pmid":"38698645","year":"2024","title":"Effect of exogenous oestrogen treatment frequency on induction of artificial lactation in pseudopregnant sows.","finding":"","journal":"Reproduction in domestic animals = Zuchthygiene","studyType":"Clinical Study"},{"pmid":"36752079","year":"2023","title":"Effect of pseudopregnancy duration in nonpregnant sows on induced lactation.","finding":"","journal":"Animal science journal = Nihon chikusan Gakkaiho","studyType":"Clinical Study"}],"tags":[{"label":"Estrogen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Estrogens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"estradiol propionate","offLabel":[],"synonyms":["estradiol dipropionate","dimenformon dipropionate","estradiol propionate"],"timeline":[],"approvals":[],"brandName":"Estradiol Propionate","ecosystem":[],"mechanism":{"moaClass":"Estrogen Receptor Agonists","modality":"Small Molecule","drugClass":"Estrogen","explanation":"Think of estrogen as a key that unlocks certain doors in your body, allowing it to function properly. Estradiol propionate is a synthetic version of that key, which can help unlock these doors and restore balance to your body's systems. This can be especially helpful for women who are experiencing hormonal imbalances or deficiencies.","oneSentence":"Estradiol propionate works by binding to estrogen receptors in the body, mimicking the effects of the naturally occurring hormone estrogen.","technicalDetail":"Estradiol propionate is a prodrug that is metabolized to estradiol, which then binds to estrogen receptors (ERα and ERβ) in various tissues, including the uterus, breast, and brain, exerting its estrogenic effects."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Estradiol_dipropionate","title":"Estradiol dipropionate","extract":"Estradiol dipropionate (EDP), sold under the brand names Agofollin, Di-Ovocylin, and Progynon DP among others, is an estrogen medication which has been used in hormone therapy for menopausal symptoms and low estrogen levels in women and in the treatment of gynecological disorders. It has also been used in feminizing hormone therapy for transgender women and in the treatment of prostate cancer in men. Although widely used in the past, estradiol dipropionate has largely been discontinued and is mostly no longer available today. It appears to remain in use only in Japan, Macedonia, and Australia. Estradiol dipropionate is given by injection into muscle at intervals ranging from once or twice a week to once every week and a half to two weeks.","wiki_history":"==History==\nEstradiol dipropionate was first synthesized and patented in 1937. It was assessed in clinical studies by 1939 and was introduced by Ciba as an oil solution for use by intramuscular injection under the brand name Di-Ovocylin by the same year. Other formulations such as Ovocyclin P by Ciba, Progynon DP by Schering and Dimenformon Dipropionate by Roche-Organon were also marketed by the early 1940s. Later in the 1940s the brand name Di-Ovocylin was changed by Ciba to Ovocylin Dipropionate. Along with estradiol benzoate, which was introduced in 1933, estradiol dipropionate was one of the first estradiol esters to be introduced for medical use. Prior to the development and introduction of longer-acting estradiol esters like estradiol valerate and estradiol cypionate in the 1950s, estradiol dipropionate and estradiol benzoate were the most widely used estradiol esters.","wiki_society_and_culture":"==Society and culture==\n\n===Generic names===\nEstradiol dipropionate is the generic name of the drug and its , , and .\n\n===Availability===\nEstradiol dipropionate has been discontinued in most countries, but remains available in Japan and Macedonia alone under the brand names Ovahormon and Oestradiol Galenika and/or in combination with hydroxyprogesterone caproate under the brand name EP Hormone Depot. It is also marketed for use in veterinary medicine in combination with hydroxyprogesterone caproate and nandrolone decanoate under the brand name Reepair in Australia."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1060","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=estradiol%20dipropionate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=estradiol dipropionate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Estradiol_dipropionate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:04:06.709970","biosimilars":[],"competitors":[],"genericName":"estradiol dipropionate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07420218","phase":"PHASE4","title":"Menopausal Hormones and Sympathetic Activation","status":"NOT_YET_RECRUITING","sponsor":"University of Delaware","startDate":"2026-09-01","conditions":["Perimenopausal Women"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":["Breast Cancer"],"enrollment":258,"completionDate":"2027-01-10"},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":["Advanced Malignant Solid Neoplasm","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Malignant Solid Neoplasm","Malignant Female Reproductive System Neoplasm","Metastatic HER2-Negative Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":2900,"completionDate":"2030-07-01"},{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":["FHA (Functional Hypothalamic Amenorrhea)"],"enrollment":114,"completionDate":"2029-04"},{"nctId":"NCT06726148","phase":"PHASE1,PHASE2","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-03","conditions":["Advanced HR+/HER2- Breast Cancer","Advanced CCNE1-amplified Solid Tumors"],"enrollment":280,"completionDate":"2028-09-25"},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":["Breast Cancer"],"enrollment":193,"completionDate":"2026-12"},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":["Breast Cancer"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT05601440","phase":"PHASE2","title":"Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2023-06-13","conditions":["Breast Cancer"],"enrollment":484,"completionDate":"2028-06-30"},{"nctId":"NCT07496294","phase":"NA","title":"Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2026-04","conditions":["Menopausal Women","Menopausal Symptom Relief","Hormone Therapy","Menopausal Hormone Therapy"],"enrollment":200,"completionDate":"2027-10"},{"nctId":"NCT06998407","phase":"PHASE1,PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":["HR+/HER2- Breast Cancer","HR+, HER2-, Advanced Breast Cancer"],"enrollment":380,"completionDate":"2030-08"},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":["Solid Tumor, Adult","Metastatic Breast Cancer","Advanced Breast Cancer","HER2 Mutation-Related Tumors","HER2-positive Metastatic Breast Cancer","KRAS Mutant Metastatic Colorectal Cancer","Metastatic Lung Cancer","Metastatic Colorectal Cancer","Advanced Lung Cancer","HR-positive, HER2-negative Advanced Breast Cancer","HER2-positive Advanced Breast Cancer"],"enrollment":392,"completionDate":"2028-11"},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":["Metastatic Breast Cancer"],"enrollment":120,"completionDate":"2028-10-07"},{"nctId":"NCT06851754","phase":"PHASE3","title":"Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2025-07-17","conditions":["Premature Ovarian Insufficiency"],"enrollment":185,"completionDate":"2031-12-31"},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":["Locoregional Recurrence","Hormone Receptor-positive Breast Cancer","HER2-negative Breast Cancer"],"enrollment":200,"completionDate":"2029-08"},{"nctId":"NCT07109726","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","status":"RECRUITING","sponsor":"Terremoto Biosciences Inc.","startDate":"2025-09-23","conditions":["Breast Cancer","Endometrial Cancer","Ovarian Cancer","Lung Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Esophageal Squamous Cell Carcinoma","Solid Tumor","Cervical Cancer"],"enrollment":205,"completionDate":"2029-02-28"},{"nctId":"NCT07347600","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-01-21","conditions":["Locally Advanced Breast Cancer","Metastatic Breast Cancer"],"enrollment":500,"completionDate":"2029-09-09"},{"nctId":"NCT06239376","phase":"NA","title":"Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-02-19","conditions":["Adenomyosis","IVF","Frozen Embryo Transfer"],"enrollment":222,"completionDate":"2027-01-02"},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":["Breast Neoplasms","Neoplasm Metastasis"],"enrollment":920,"completionDate":"2033-05"},{"nctId":"NCT05573126","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":["Hormone Receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":95,"completionDate":"2028-02"},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":["Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer"],"enrollment":303,"completionDate":"2027-08-25"},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":["Vestibulodynia","Temporomandibular Disorder","Fibromyalgia Syndrome","Irritable Bowel Syndrome","Migraines","Tension Headache","Endometriosis","Interstitial Cystitis","Back Pain","Chronic Fatigue Syndrome"],"enrollment":209,"completionDate":"2024-05-30"},{"nctId":"NCT06318403","phase":"PHASE2","title":"Estradiol Supplementation and Rotator Cuff Repair","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2028-03","conditions":["Rotator Cuff Tears","Rotator Cuff Injuries","Rotator Cuff Syndrome","Menopause Related Conditions","Menopause"],"enrollment":58,"completionDate":"2030-12"},{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":["Fertility"],"enrollment":24,"completionDate":"2026-03-09"},{"nctId":"NCT00099437","phase":"PHASE3","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2005-02-13","conditions":["Breast Cancer"],"enrollment":736,"completionDate":"2026-12-31"},{"nctId":"NCT07226349","phase":"PHASE1","title":"A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":["Advanced Solid Tumor"],"enrollment":105,"completionDate":"2029-03-15"},{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":["Advanced Breast Cancer"],"enrollment":624,"completionDate":"2028-05-15"},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":["Advanced Solid Tumor","Advanced Breast Cancer","Metastatic Breast Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Malignant Neoplasm of Breast","HER2-negative Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Non-small Cell Lung Cancer"],"enrollment":300,"completionDate":"2028-06"},{"nctId":"NCT07480681","phase":"PHASE1","title":"Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":["Advanced/Metastatic Solid Tumors"],"enrollment":138,"completionDate":"2028-06"},{"nctId":"NCT07358468","phase":"","title":"Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2026-02-22","conditions":["Infertility","Endometrial Peristalsis","Uterine Contraction","Endometrial Waves","Frozen Embryo Transfer (FET)","Uterine Peristalsis"],"enrollment":356,"completionDate":"2027-12-01"},{"nctId":"NCT07038369","phase":"PHASE1","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atavistik Bio, Inc","startDate":"2025-07-29","conditions":["Advanced Solid Tumors","Breast Cancer","Breast Carcinoma","Breast Neoplasms","ER Positive Breast Cancer","Cervical Cancers","Cervical Neoplasms","Cervical Carcinoma","Triple Negative Breast Cancer","Gynecologic Cancers","Gynecologic Neoplasm","Endometrial Cancer","Endometrial Neoplasm","Endometrial Carcinoma (EC)","Fallopian Cancer","Ovarian Carcinoma","Ovarian Cancer","Ovarian Neoplasms","Prostate Cancers","Prostate Carcinoma","Solid Tumors","Neoplasms","Neoplasms by Site","Breast Diseases","Uterine Neoplasms","Genital Neoplasms, Female","Urogenital Neoplasms"],"enrollment":134,"completionDate":"2029-01-31"},{"nctId":"NCT06993844","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":["Advanced Solid Tumors","Advanced Breast Cancer"],"enrollment":233,"completionDate":"2027-12-30"},{"nctId":"NCT04191499","phase":"PHASE2,PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-29","conditions":["Breast Cancer"],"enrollment":325,"completionDate":"2027-11-15"},{"nctId":"NCT06997029","phase":"PHASE1","title":"A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-08-01","conditions":["Advanced Solid Tumor","Advanced Breast Cancer","Advanced Ovarian Cancer"],"enrollment":234,"completionDate":"2028-12-14"},{"nctId":"NCT03643510","phase":"PHASE2","title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-21","conditions":["Adenocarcinoma of Endometrium"],"enrollment":28,"completionDate":"2026-03-12"},{"nctId":"NCT05230810","phase":"PHASE1,PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":["HER2-positive Metastatic Breast Cancer"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT07235774","phase":"PHASE1","title":"A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-11-05","conditions":["Healthy Adult Female Participants"],"enrollment":28,"completionDate":"2026-03-13"},{"nctId":"NCT03424005","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":["Metastatic Breast Cancer"],"enrollment":792,"completionDate":"2030-09-30"},{"nctId":"NCT07368998","phase":"PHASE2","title":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-02-18","conditions":["Breast Cancer"],"enrollment":80,"completionDate":"2031-10-31"},{"nctId":"NCT07043322","phase":"PHASE2","title":"Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-06-30","conditions":["Gynecologic Disease"],"enrollment":150,"completionDate":"2026-11-20"},{"nctId":"NCT06016738","phase":"PHASE3","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2023-11-16","conditions":["Breast Cancer","Advanced Breast Cancer","Metastatic Breast Cancer","ER Positive Breast Cancer","HER2 Negative Breast Carcinoma"],"enrollment":510,"completionDate":"2027-09-30"},{"nctId":"NCT06736704","phase":"PHASE1,PHASE2","title":"SNV4818 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pikavation Therapeutics, Inc.","startDate":"2025-02-20","conditions":["Advanced Solid Tumors"],"enrollment":320,"completionDate":"2027-06"},{"nctId":"NCT07287917","phase":"PHASE1,PHASE2","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aminex Therapeutics, Inc.","startDate":"2026-01-26","conditions":["Melanoma (Skin Cancer)","HER2-low Hormone Receptor Positive Breast Cancer"],"enrollment":92,"completionDate":"2028-12-29"},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":["Castration-Sensitive Prostate Adenocarcinoma","Metastatic Castration-Sensitive Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":60,"completionDate":"2029-06-01"},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":["Advanced Breast Cancer"],"enrollment":500,"completionDate":"2030-10-18"},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"enrollment":895,"completionDate":"2029-08-14"},{"nctId":"NCT06513104","phase":"PHASE1","title":"A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-07-18","conditions":["Diabetes Mellitus, Type 2"],"enrollment":47,"completionDate":"2025-09-30"},{"nctId":"NCT05524584","phase":"PHASE2","title":"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-31","conditions":["Breast Cancer","Metastatic Breast Cancer","Hormone Receptor-positive Breast Cancer","HER2-negative Breast Cancer"],"enrollment":20,"completionDate":"2031-12-31"},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":["Breast Cancer","Solid Tumor"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT06506955","phase":"PHASE2,PHASE3","title":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","status":"ENROLLING_BY_INVITATION","sponsor":"Taiho Oncology, Inc.","startDate":"2024-10-01","conditions":["Advanced/Metastatic Cancer"],"enrollment":15,"completionDate":"2027-04-30"},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":["Breast Neoplasms"],"enrollment":51,"completionDate":"2027-03-31"},{"nctId":"NCT05457972","phase":"PHASE4","title":"Postpartum Vaginal Estrogen for Breastfeeding Patients","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2025-02-22","conditions":["Breastfeeding","Postpartum Sexual Dysfunction","Vaginal Atrophy"],"enrollment":100,"completionDate":"2026-09-30"},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":["Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"],"enrollment":1050,"completionDate":"2029-02-12"},{"nctId":"NCT07405801","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":["Breast Cancer"],"enrollment":80,"completionDate":"2030-12-30"},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":["Malignant Neoplasm"],"enrollment":250,"completionDate":"2027-11-04"},{"nctId":"NCT03941730","phase":"PHASE2","title":"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-08-28","conditions":["Advanced Triple-Negative Breast Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma","Recurrent Breast Carcinoma"],"enrollment":8,"completionDate":"2026-12-31"},{"nctId":"NCT04451746","phase":"NA","title":"The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases","status":"COMPLETED","sponsor":"Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia","startDate":"2020-06-24","conditions":["Chronic Venous Diseases"],"enrollment":116,"completionDate":"2026-02-23"},{"nctId":"NCT03531645","phase":"PHASE2","title":"Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":["Malignant Neoplasms of Female Genital Organs"],"enrollment":18,"completionDate":"2027-09-30"},{"nctId":"NCT05551949","phase":"PHASE4","title":"Preventing Recurrent UTI With Vaginal Estrogen","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-01-01","conditions":["Recurrent Urinary Tract Infection","Urinary Tract Infections","Cystitis Recurrent"],"enrollment":27,"completionDate":"2025-08-31"},{"nctId":"NCT06257264","phase":"PHASE1","title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-03-11","conditions":["Breast Cancer","Small Cell Lung Cancer","Ovarian Cancer","Gastric Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Advanced Solid Tumor","Endometrial Cancer","Prostate Cancer","TNBC - Triple-Negative Breast Cancer","GastroEsophageal Cancer","Bladder Cancer"],"enrollment":258,"completionDate":"2028-07"},{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":["Healthy Participants"],"enrollment":75,"completionDate":"2026-12-25"},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":["Autosomal Dominant Polycystic Kidney Disease (ADPKD)"],"enrollment":74,"completionDate":"2026-07-04"},{"nctId":"NCT05554354","phase":"PHASE2","title":"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":1,"completionDate":"2025-04-04"},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":["Healthy Volunteers"],"enrollment":48,"completionDate":"2026-06-12"},{"nctId":"NCT05154487","phase":"PHASE2","title":"A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GOG Foundation","startDate":"2024-09-11","conditions":["Endometroid Endometrial Cancer"],"enrollment":51,"completionDate":"2028-11-01"},{"nctId":"NCT06982521","phase":"PHASE3","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2025-08-26","conditions":["PIK3CA Mutation","HER2- Negative Breast Cancer","Hormone Receptor Positive Tumor","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer"],"enrollment":540,"completionDate":"2031-12-31"},{"nctId":"NCT01560416","phase":"PHASE2","title":"Fulvestrant With or Without Ganetespib in HR+ Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-06","conditions":["Breast Cancer"],"enrollment":50,"completionDate":"2016-06-26"},{"nctId":"NCT05768139","phase":"PHASE1,PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":["Breast Cancer","Solid Tumors, Adult"],"enrollment":720,"completionDate":"2030-07"},{"nctId":"NCT07254429","phase":"PHASE2","title":"COMPASS - COpenhagen MenoPAuSe Study","status":"RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-10-02","conditions":["Menopausal Osteoporosis","Bone Markers"],"enrollment":192,"completionDate":"2028-05"},{"nctId":"NCT07389733","phase":"PHASE1,PHASE2","title":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-02","conditions":["Advanced Unresectable or Metastatic Breast Cancer of Adults"],"enrollment":180,"completionDate":"2028-12"},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Unresectable HER2-Negative Breast Carcinoma","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":60,"completionDate":"2028-06-01"},{"nctId":"NCT02860000","phase":"PHASE2","title":"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-07-06","conditions":["Estrogen Receptor Status","HER2/Neu Negative","Invasive Breast Carcinoma","Postmenopausal","Stage III Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer"],"enrollment":96,"completionDate":"2025-02-14"},{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":["Hormone Receptor Positive Breast Cancer"],"enrollment":462,"completionDate":"2026-01-16"},{"nctId":"NCT07032506","phase":"NA","title":"Intrauterine Stent Placement Following Hysteroscopic Septum Resection","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-03","conditions":["Intrauterine Adhesion"],"enrollment":320,"completionDate":"2031-12-31"},{"nctId":"NCT01597388","phase":"PHASE1","title":"AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05-08","conditions":["Advanced Metastatic Breast Cancer"],"enrollment":99,"completionDate":"2026-01-13"},{"nctId":"NCT02778685","phase":"PHASE2","title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-09-30","conditions":["Metastatic Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":47,"completionDate":"2026-03-30"},{"nctId":"NCT07426822","phase":"PHASE2","title":"Rash & Diarrhea Prophylaxis With Capivasertib","status":"NOT_YET_RECRUITING","sponsor":"Maryam Lustberg","startDate":"2026-04","conditions":["Metastatic HR+/HER2- Breast Cancer"],"enrollment":108,"completionDate":"2029-04"},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":["Advanced Breast Carcinoma","HER2-Positive Breast Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","HER2-positive Breast Cancer"],"enrollment":17,"completionDate":"2026-06-13"},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":["Breast Cancer Metastatic"],"enrollment":367,"completionDate":"2025-01-02"},{"nctId":"NCT07408089","phase":"PHASE1","title":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2026-02-25","conditions":["Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer"],"enrollment":96,"completionDate":"2029-05-31"},{"nctId":"NCT03905941","phase":"EARLY_PHASE1","title":"Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2021-08-23","conditions":["Polycystic Ovary Syndrome"],"enrollment":0,"completionDate":"2024-11-25"},{"nctId":"NCT06307184","phase":"","title":"Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer","status":"RECRUITING","sponsor":"Instituto Valenciano de Infertilidade de Lisboa","startDate":"2024-02-23","conditions":["Frozen Embryo Transfer"],"enrollment":530,"completionDate":"2026-12"},{"nctId":"NCT06494150","phase":"PHASE2","title":"Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":["Low Grade Ovarian Serous Adenocarcinoma"],"enrollment":37,"completionDate":"2029-09"},{"nctId":"NCT07288359","phase":"PHASE1,PHASE2","title":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-29","conditions":["Advanced HR+/HER2- Breast Cancer","Advanced CCNE1-amplified Solid Tumors","Metastatic Castration-resistant Prostate Cancer"],"enrollment":205,"completionDate":"2031-05-09"},{"nctId":"NCT05022342","phase":"","title":"Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-27","conditions":["Breast Cancer"],"enrollment":595,"completionDate":"2025-02-11"},{"nctId":"NCT07229209","phase":"NA","title":"Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-02-05","conditions":["Abnormal Uterine Bleeding","Cesarean Section Complications","Uterine Scar"],"enrollment":166,"completionDate":"2025-11-01"},{"nctId":"NCT05038735","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":["Breast Cancer"],"enrollment":212,"completionDate":"2027-03-02"},{"nctId":"NCT07422506","phase":"NA","title":"A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-01-01","conditions":["Missed Abortion","Early Pregnancy Failure"],"enrollment":580,"completionDate":"2035-01-01"},{"nctId":"NCT05672901","phase":"NA","title":"Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"Stratpharma AG","startDate":"2023-04-04","conditions":["Genitourinary Syndrome of Menopause"],"enrollment":100,"completionDate":"2026-09"},{"nctId":"NCT07419594","phase":"NA","title":"Estradiol and Intrusive Memories","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-08-19","conditions":["PTSD","Intrusive Memories","Intrusion Symptom","Trauma","Intrusion"],"enrollment":273,"completionDate":"2028-02-29"},{"nctId":"NCT07419776","phase":"","title":"The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-06-24","conditions":["Poly Cystic Ovary Syndrome"],"enrollment":90,"completionDate":"2025-11-20"},{"nctId":"NCT07288190","phase":"PHASE2","title":"Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR","status":"NOT_YET_RECRUITING","sponsor":"HIV Prevention Trials Network","startDate":"2026-05-15","conditions":["Pregnancy","HIV Infections"],"enrollment":300,"completionDate":"2028-05-15"},{"nctId":"NCT06852365","phase":"PHASE2","title":"Combined Oral Contraceptive Pill and Resistance Starch","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-06-10","conditions":["Metabolic Syndrome","Polycystic Ovary Syndrome"],"enrollment":100,"completionDate":"2028-04"},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":["Mild Cognitive Impairment","Dementia, Mild"],"enrollment":73,"completionDate":"2026-02-09"},{"nctId":"NCT05317364","phase":"PHASE4","title":"Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2022-07-14","conditions":["Obstetric; Injury Pelvic Floor","Sexual Dysfunction","Anal Incontinence","Urinary Incontinence"],"enrollment":38,"completionDate":"2026-02-13"},{"nctId":"NCT07100782","phase":"PHASE3","title":"Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-12-08","conditions":["Endometriosis","Pelvic Pain"],"enrollment":130,"completionDate":"2028-09"},{"nctId":"NCT07416578","phase":"NA","title":"Clinical Study on the Effect of Umbilical Cord Mesenchymal Stem Cell Exosomes on Endometrial Repair of Intrauterine Adhesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-01-01","conditions":["Intrauterine Adhesions","Exosomes"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT07414784","phase":"PHASE1","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-11","conditions":["Healthy Volunteer"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":333,"completionDate":"2028-01-21"},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":["HER-2 Positive Breast Cancer","Estrogen Receptor Positive Breast Cancer"],"enrollment":518,"completionDate":"2026-07-31"},{"nctId":"NCT05101564","phase":"PHASE2","title":"Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2023-03-20","conditions":["Breast Cancer","HER2-negative Breast Cancer","ER Positive Breast Cancer"],"enrollment":19,"completionDate":"2024-06-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"4684","NDDF":"001265","UNII":"NIG5418BXB","CHEBI":"CHEBI:31560","VANDF":"4017609","INN_ID":"406","RXNORM":"4083","UMLSCUI":"C0059618","ChEMBL_ID":"CHEMBL1697791","KEGG_DRUG":"D01617","DRUGBANK_ID":"DB00783","PDB_CHEM_ID":" EST","PUBCHEM_CID":"8225","SNOMEDCT_US":"126172005","MESH_DESCRIPTOR_UI":"D004958","MESH_SUPPLEMENTAL_RECORD_UI":"C023482"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":199,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct 24","pmid":"41137228","title":"Synergistic target network construction and dynamic simulation analysis based on a prospective systems pharmacology strategy.","journal":"Medicine"},{"date":"2025 Aug","pmid":"40719002","title":"Multiple Estradiol Benzoate Treatment Enhances Milk Production on Induction of Artificial Lactation in Pseudopregnant Pigs.","journal":"Reproduction in domestic animals = Zuchthygiene"},{"date":"2025 Sep","pmid":"39840814","title":"Structure and hormonal output of the adrenal gland after experimental estrogenization of male rats.","journal":"Histology and histopathology"},{"date":"2024 May","pmid":"38698645","title":"Effect of exogenous oestrogen treatment frequency on induction of artificial lactation in pseudopregnant sows.","journal":"Reproduction in domestic animals = Zuchthygiene"},{"date":"2023 Jan-Dec","pmid":"36752079","title":"Effect of pseudopregnancy duration in nonpregnant sows on induced lactation.","journal":"Animal science journal = Nihon chikusan Gakkaiho"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Estradiol Propionate, also known as estradiol dipropionate, is a synthetic estrogen medication. It is a small molecule that works by binding to estrogen receptors in the body, mimicking the effects of the naturally occurring hormone estrogen. However, due to the lack of available information, its specific target and indications are unknown. The commercial status of estradiol propionate is also unclear, with no information available on its patent status or generic manufacturers. As a result, its safety considerations and pharmacokinetic properties, such as half-life and bioavailability, remain unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}